Talk:Vutrisiran

The user below has a request that an edit be made to Vutrisiran. That user has an actual or apparent conflict of interest. The requested edits backlog is very high. Please be extremely patient. There are currently 437 requests waiting for review. Please read the instructions for the parameters used by this template for accepting and declining them, and review the request below and make the edit if it is well sourced, neutral, and follows other Wikipedia guidelines and policies.

Hello, I have copied the following from my user page, as it is way out of my area of knowledge. Wondered if someone could take a look and see if it is reasonable to apply something to the article. Have not tagged with a COI edit request as probably needs further details from the user. Keith D (talk) 22:59, 27 March 2026 (UTC)

Hello Keith D, my name is Julia and I am a Public Relations professional at Uncapped Communications. We’re reaching out on behalf of our clients at Alnylam in search of an editor to update outdated information found on the AMVUTTRA Wikipedia page.

We understand Wikipedia users depend on active, qualified editors to help ensure articles are accurate and well supported. In the interest of transparency, we are also aware that, per Wikipedia’s guidelines, neither the company nor its representatives can make direct edits to Wikipedia pages.

Respecting these rules, our priority is ensuring that the article reflects the most current publicly available information. Since the page was last updated, the U.S. Food and Drug Administration has approved an updated indication for AMVUTTRA, and we wanted to make sure the article accurately reflects any relevant changes based on publicly available sources. Uncapped (talk) 13:25, 26 March 2026 (UTC)

@Uncapped: Hello, would be good if you could link to the article you want to update and give details of the changes that you want to make. You would also have to supply references to support the changes from third-party sources rather than those related to the company. Keith D (talk) 17:41, 26 March 2026 (UTC)

Hi Keith, thank you for your response. The article we are referring to is the Vutrisiran Wikipedia page: Vutrisiran - Wikipedia. The update we wanted to flag is that AMVUTTRA® (vutrisiran) received U.S. FDA approval for an additional indication on March 20, 2025, for the for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. At a high level, the page appears to reflect AMVUTTRA’s earlier approval history and does not yet include this expanded indication.

To support this update, please see news articles covering the approval below:

• AJMC: FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
• FiercePharma: Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with Pfizer
• Medscape: FDA Expands Vutrisiran Indication to ATTR Cardiomyopathy

Uncapped (talk) 20:51, 27 March 2026 (UTC)